Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and gfr decline in autosomal dominant polycystic kidney disease: Results from the crisp cohort

American Journal of Kidney Diseases

Volumn 61, Issue 3, 2013, Pages 420-429

  Boertien, Wendy E ^a   Meijer, Esther ^a   Li, Jie ^b   Bost, James E ^b   Struck, Joachim ^c   Flessner, Michael F ^d   Gansevoort, Ron T ^a   Torres, Vicente E ^e  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c THERMO FISHER SCIENTIFIC   (Germany)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e Mayo Clinic   (United States)

Author keywords

arginine vasopressin; Autosomal dominant polycystic kidney disease; copeptin; disease progression; glomerular filtration rate; kidney function; polycystic kidney disease; total kidney volume

Indexed keywords

ARGIPRESSIN; COPEPTIN; IOTALAMIC ACID;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CREATININE CLEARANCE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA OSMOLALITY; URINE OSMOLALITY;

ADULT; ARGININE VASOPRESSIN; BIOLOGICAL MARKERS; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOPEPTIDES; HUMANS; KIDNEY; LONGITUDINAL STUDIES; MALE; ORGAN SIZE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; YOUNG ADULT;

EID: 84874117983     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.08.038     Document Type: Article

References (32)

1. V.E. Torres, P.C. Harris, Y. Pirson Autosomal dominant polycystic kidney disease Lancet 369 9569 2007 1287 1301
2. F.A. Belibi, G. Reif, D.P. Wallace Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells Kidney Int 66 3 2004 964 973
3. J.J. Grantham Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease Understanding polycystic kidney disease: a systems biology approach Kidney Int 64 4 2003 1157 1162
4. G.L. Robertson, E.A. Mahr, S. Athar, T. Sinha Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma J Clin Invest 52 9 1973 2340 2352
5. N.G. Morgenthaler, J. Struck, C. Alonso, A. Bergmann Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin Clin Chem 52 1 2006 112 119
6. N.G. Morgenthaler, J. Struck, S. Jochberger, M.W. Dunser Copeptin: clinical use of a new biomarker Trends Endocrinol Metab 19 2 2008 43 49
7. G. Szinnai, N.G. Morgenthaler, K. Berneis Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects J Clin Endocrinol Metab 92 10 2007 3973 3978
8. E. Meijer, S.J. Bakker, E.J. van der Jagt Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease Clin J Am Soc Nephrol 6 2 2010 361 368
9. Boertien WE, Meijer E, Zittema D, et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease [published ahead of print April 20, 2012]. Nephrol Dial Transplant. doi:10.1093/ndt/gfs070.
10. A.B. Chapman, L.M. Guay-Woodford, J.J. Grantham Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort Kidney Int 64 3 2003 1035 1045
11. J.J. Grantham, A.B. Chapman, V.E. Torres Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes Clin J Am Soc Nephrol 1 1 2006 148 157
12. B.F. King, V.E. Torres, M.E. Brummer Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease Kidney Int 64 6 2003 2214 2221
13. A.D. Rule, V.E. Torres, A.B. Chapman Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the Consortium of Radiologic Imaging Studies of Polycystic Kidney Disease cohort J Am Soc Nephrol 17 3 2006 854 862
14. V.E. Torres, J.J. Grantham, A.B. Chapman Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease Clin J Am Soc Nephrol 6 3 2011 640 647
15. D. Ravine, R.N. Gibson, R.G. Walker Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1 Lancet 343 8901 1994 824 827
16. W. Fenske, S. Stork, A. Blechschmidt Copeptin in the differential diagnosis of hyponatremia J Clin Endocrinol Metab 94 1 2009 123 129
17. P. Marckmann, L. Skov, K. Rossen Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging J Am Soc Nephrol 17 2006 2359 2362
18. A. Levin Identification of patients and risk factors in chronic kidney disease - evaluating risk factors and therapeutic strategies Nephrol Dial Transplant 16 suppl 7 2001 57 60
19. E. Meijer, S.J. Bakker, N. Halbesma Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort Kidney Int 77 1 2010 29 36
20. E. Meijer, S.J. Bakker, P.E. de Jong Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients Transplantation 88 4 2009 561 567
21. D. Zittema, W.E. Boertien, A.P. van Beek Vasopressin, copeptin and renal concentrating capacity in ADPKD patients without renal impairment Clin J Am Soc Nephrol 7 6 2012 906 913
22. E. Meijer, M. Rook, H. Tent Early renal abnormalities in autosomal dominant polycystic kidney disease Clin J Am Soc Nephrol 5 6 2010 1091 1098
23. H. Wong, L. Vivian, G. Weiler, G. Filler Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease Am J Kidney Dis 43 4 2004 624 628
24. E. Meijer, R.T. Gansevoort, P.E. de Jong Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug Nephrol Dial Transplant 26 8 2011 2445 2453
25. X. Wang, V. Gattone, P.C. Harris, V.E. Torres Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat J Am Soc Nephrol 16 4 2005 846 851
26. V.E. Torres, X. Wang, Q. Qian Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease Nat Med 10 4 2004 363 364
27. V.H. Gattone, X. Wang, P.C. Harris, V.E. Torres Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist Nat Med 9 10 2003 1323 1326
28. S. Nagao, K. Nishii, M. Katsuyama Increased water intake decreases progression of polycystic kidney disease in the PCK rat J Am Soc Nephrol 17 8 2006 2220 2227
29. E. Higashihara, V.E. Torres, A.B. Chapman Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience Clin J Am Soc Nephrol 6 10 2011 2499 2507
30. V.E. Torres, E. Meijer, K.T. Bae Rationale and design of the TEMPO 3/4 study, Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes Am J Kidney Dis 57 5 2011 692 699
31. M.V. Irazabal, V.E. Torres, M.C. Hogan Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease Kidney Int 80 3 2011 295 301
32. P. Ruggenenti, A. Remuzzi, P. Ondei Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease Kidney Int 68 1 2005 206 216